Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
PeptiGrowth Inc. is Launching a Novel Synthetic FGF2 Alternative Peptide (FGFR1c Agonist) 2024-10-01 21:00
NUS researchers develop revolutionary technology to unravel complex protein interactions that could transform cancer diagnostics 2024-09-30 15:51
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia 2024-09-30 15:00
IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment 2024-09-30 13:48
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population 2024-09-30 13:42
Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer 2024-09-30 13:00
SeromYx Systems and ACROBiosystems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies 2024-09-29 21:00
IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel（FucasoTM）in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting 2024-09-29 21:00
New Beginnings, New Journey | Sanyou Opening of New 10,000-sqm Facility, Ushering in a New Era of Innovation for Bio Drugs 2024-09-28 20:00
IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting 2024-09-27 15:41
Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria 2024-09-26 15:10
The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA 2024-09-25 21:18
Samsung Biologics launches development platforms for enhanced therapeutic efficacy 2024-09-25 19:00
LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners 2024-09-24 21:00
Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Generation Immunotherapeutics Discovery 2024-09-24 20:00
Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024 2024-09-23 17:40
WuXi Biologics Included in Hang Seng ESG 50 Index 2024-09-23 17:30
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting 2024-09-20 20:30
Kangpu Completed Bridging Clinical Study of KPG-818 in China 2024-09-20 20:00
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001 2024-09-20 16:28
1 5 6 7 8 9 222